NeuBase Therapeutics, Inc.: 10-Q filed 2016-02-09

Name: NeuBase Therapeutics, Inc.: 10-Q filed 2016-02-09
Creator: NeuBase Therapeutics, Inc.

What NeuBase Therapeutics, Inc. reported in its quarterly report filed 2016-02-09 (fiscal Q1 2016): 20 published measures, 40 facts as tagged in accession 0001387131-16-004111.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-02-09
Fiscal period: fiscal Q1 2016
Accession: 0001387131-16-004111 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuBase Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-12-31	44,151,136	USD
At 2015-09-30	46,370,807	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-12-31	5,276,886	USD
At 2015-09-30	3,880,014	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-12-31	38,874,250	USD
At 2015-09-30	42,490,793	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-6,145,462	USD	92
2014-10-01 to 2014-12-31	-4,598,337	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-12-31	-64,656,875	USD
At 2015-09-30	-58,511,413	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-12-31	244,261	USD
At 2015-09-30	248,753	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	316,819	USD	92
2014-10-01 to 2014-12-31	362,028	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-3,592,148	USD	92
2014-10-01 to 2014-12-31	-3,923,987	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-12-31	27,103,555	USD
At 2015-09-30	29,036,036	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-12-31	5,276,886	USD
At 2015-09-30	3,880,014	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2015-12-31	740,912	USD
At 2015-09-30	740,912	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2015-12-31	16,050,165	USD
At 2015-09-30	16,332,863	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	2,076,280	USD	92
2014-10-01 to 2014-12-31	2,805,896	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-12-31	30,956,112	shares
At 2015-09-30	30,331,309	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2015-12-31	103,528,029	USD
At 2015-09-30	100,999,173	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-6,145,462	USD	92
2014-10-01 to 2014-12-31	-4,598,337	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	1,218,128	USD	92
2014-10-01 to 2014-12-31	812,469	USD	92

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	15,042	USD	92
2014-10-01 to 2014-12-31	7,636	USD	92

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	282,698	USD	92
2014-10-01 to 2014-12-31	297,986	USD	92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-2,553,314	USD	92
2014-10-01 to 2014-12-31	-674,350	USD	92

Inspect the source

Entity: NeuBase Therapeutics, Inc. / CIK 0001173281
Captured: 2026-09-22 19:42 UTC
SEC response SHA-256: 0e0882fa147fcb0a3e5f3af54573abe947d9ade4d42095debd16c2d62da36e79

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001173281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))